4,300 Shares in GeneDx Holdings Corp. $WGS Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB acquired 4,300 shares of GeneDx Holdings Corp. valued at $397,000 in Q2. Other investors like Westfield Capital and Ensign Peak Advisors also increased their holdings. GeneDx's stock performance shows significant growth, with a 12-month high of $170.75. Analysts have mixed ratings, with some upgrading and others downgrading the stock. Insider trading activity includes significant stock sales by CEO Katherine Stueland and Director Joshua Ruch.

Handelsbanken Fonder AB bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,300 shares of the company's stock, valued at approximately $397,000.

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

A number of other large investors have also recently modified their holdings of WGS. Westfield Capital Management Co. LP grew its holdings in shares of GeneDx by 164.8% during the second quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company's stock worth $54,388,000 after purchasing an additional 366,711 shares in the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of GeneDx by 3,716.1% in the 2nd quarter. Ensign Peak Advisors Inc now owns 57,242 shares of the company's stock worth $5,284,000 after buying an additional 55,742 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of GeneDx by 23.2% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 18,875 shares of the company's stock valued at $1,742,000 after buying an additional 3,558 shares in the last quarter. Cetera Investment Advisers bought a new stake in shares of GeneDx during the 2nd quarter worth $249,000. Finally, Intech Investment Management LLC grew its position in GeneDx by 133.1% in the second quarter. Intech Investment Management LLC now owns 15,129 shares of the company's stock worth $1,397,000 after acquiring an additional 8,639 shares in the last quarter. Institutional investors own 61.72% of the company's stock.

Insider Activity

In related news, CEO Katherine Stueland sold 10,501 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the transaction, the chief executive officer owned 14,578 shares in the company, valued at $1,770,789.66. This represents a 41.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joshua Ruch sold 38,000 shares of GeneDx stock in a transaction on Monday, November 24th. The shares were sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the completion of the sale, the director owned 11,941 shares in the company, valued at approximately $1,914,978.17. This trade represents a 76.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 55,153 shares of company stock valued at $8,217,644. Company insiders own 29.60% of the company's stock.

GeneDx Stock Performance

GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play

Shares of NASDAQ:WGS opened at $166.77 on Monday. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average price of $130.75 and a 200-day moving average price of $107.83. The company has a market cap of $4.82 billion, a price-to-earnings ratio of 1,852.94 and a beta of 1.98. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $170.75.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.21. The company had revenue of $116.74 million for the quarter, compared to analysts' expectations of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. GeneDx has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Upgrades and Downgrades

WGS has been the subject of several research analyst reports. BTIG Research lifted their price target on GeneDx from $140.00 to $165.00 and gave the stock a "buy" rating in a research note on Wednesday, October 29th. Wall Street Zen cut GeneDx from a "buy" rating to a "hold" rating in a report on Saturday, November 1st. Canaccord Genuity Group set a $160.00 target price on GeneDx and gave the stock a "buy" rating in a research note on Wednesday, October 29th. Wells Fargo & Company lifted their price target on shares of GeneDx from $95.00 to $140.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 4th. Finally, Piper Sandler boosted their price objective on shares of GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, September 11th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $129.22.

Check Out Our Latest Research Report on WGS

About GeneDx

(Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Should You Invest $1,000 in GeneDx Right Now?

Before you consider GeneDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.

While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here